Amyotrophic Lateral Sclerosis: An overview
Keywords:
Amyotrophic lateral sclerosis (ALS), neurons, sporadic Amyotrophic lateral sclerosis (SALS), familial Amyotrophic lateral sclerosis (FALS)Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which characterized by pathogenic protein aggregates that correlate with the progressive degeneration of neurons and the loss of behavioral functions. It is now more often recognized as Lou Gehrig’s disease in the US. ALS is an uncommon disease; diagnosis is often delayed because more prevalent conditions are taken into consideration before ALS. ALS has a about 1 in 350 lifetime risk. The genes responsible for 10% of sporadic ALS and two thirds of familial A physiology and causation are still mostly unclear. A common pathogenic characteristic of both familial and sporadic ALS is toxicity, which can also result from aggregation of both wild-type and mutant proteins. The goal of ALS treatment is to maximize quality of life and use disease-modifying treatments because the condition is still incurable. This review outline about the ALS disease and discuss the status of ALS in human neurons which may improve care and outcome for ALS patients
References
1. Amyotrophic Lateral Sclerosis (ALS) Fact Sheet”. National Institute of Neurological Disorders and Stroke. Archived from the original on 5 January 2017. Retrieved 22 October 2020.
2. Masrori P, Van Damme P (October 2020). “Amyotrophic lateral sclerosis: a clinical review”. European Journal of Neurology. 27 (10): 1918–1929. Doi:10.1111/ene.14393. PMC 7540334. PMID 32526057.
3. J.M. Charcot, A. (1869). Joffroy Deux cas d’atrophie musculaire progressive avec lesion de la substance grise et des faisceaux antero-lateraux de la moelle epiniere Arch. Physiol. Neurol. Path., 2, pp. 744-754
4. Gordon, P. H., Mitsumoto, H., & Hays, A. P. (2003). Amyotrophic lateral sclerosis. Science of Aging Knowledge Environment, 2003(35), dn2-dn2.
5. Yoshida, S., Mulder, D. W., Kurland, L. T., Chu, C. P., & Okazaki, H. (1986). Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984. Neuroepidemiology, 5(2), 61-70.
6. Abe, K., Fujimura, H., Toyooka, K., Sakoda, S., Yorifuji, S., & Yanagihara, T. (1997). Cognitive function in amyotrophic lateral sclerosis. Journal of the neurological sciences, 148(1), 95-100.
7. Al-Sarraj, S., King, A., Troakes, C., Smith, B., Maekawa, S., Bodi, I., ... & Shaw, C. E. (2011). p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta neuropathologica, 122, 691-702.
8. ALS Mutation Database. (2007). The University of Tokyo;(reseq.biosciencedbc.jp/resequence/SearchDisease.do?targetId=1). [Google Scholar]
9. Swinnen, B., & Robberecht, W. (2014). The phenotypic variability of amyotrophic lateral sclerosis. Nature Reviews Neurology, 10(11), 661-670. Doi: 10.1038/nrneurol.2014.184.
10. Morgan, S., & Orrell, R. W. (2016). Pathogenesis of amyotrophic lateral sclerosis. British medical bulletin, 119(1), 87-97. Doi: 10.1093/bmb/ldw026.
11. Ryan, M., Heverin, M., McLaughlin, R. L., & Hardiman, O. (2019). Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA neurology, 76(11), 1367-1374.
12. Su, F. C., Goutman, S. A., Chernyak, S., Mukherjee, B., Callaghan, B. C., Batterman, S., & Feldman, E. L. (2016). Association of environmental toxins with amyotrophic lateral sclerosis. JAMA neurology, 73(7), 803-811.
13. Gregory, J. M., Fagegaltier, D., Phatnani, H., & Harms, M. B. (2020). Genetics of amyotrophic lateral sclerosis. Current Genetic Medicine Reports, 8, 121-131.
14. Camu, W., Khoris, J., Moulard, B., Salachas, F., Briolotti, V., Rouleau, G. A., & Meininger, V. (1999). Genetics of familial ALS and consequences for diagnosis. Journal of the neurological sciences, 165, S21-S26.
15. Haverkamp, L. J., Appel, V., & Appel, S. H. (1995). Natural history of amyotrophic lateral sclerosis in a database population Validation of a scoring system and a model for survival prediction. Brain, 118(3), 707-719.
16. Andersen, P. M. (2006). Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Current neurology and neuroscience reports, 6(1), 37-46.
17. Mackenzie, I. R., Rademakers, R., & Neumann, M. (2010). TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. The Lancet Neurology, 9(10), 995-1007.
18. Nguyen, H. P., Van Broeckhoven, C., & van der Zee, J. (2018). ALS genes in the genomic era and their implications for FTD. Trends in Genetics, 34(6), 404-423.
19. Wang, M. J., Kang, L., Wang, Y. Z., Yang, B. R., Zhang, C., Lu, Y. F., & Kang, L. (2022). Microglia in motor neuron disease: Signaling evidence from last 10 years. Developmental Neurobiology, 82(7-8), 625-638.
20. Almad, A. A., Taga, A., Joseph, J., Gross, S. K., Welsh, C., Patankar, A., ... & Maragakis, N. J. (2022). Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS. Proceedings of the National Academy of Sciences, 119(13), e2107391119.
21. Gong, Z., Ba, L., & Zhang, M. (2022). Dysfunction of the oligodendrocytes in amyotrophic lateral sclerosis. Journal of Biomedical Research, 36(5), 336.
22. Badu-Mensah, A., Guo, X., Nimbalkar, S., Cai, Y., & Hickman, J. J. (2022). ALS mutations in both human skeletal muscle and motoneurons differentially affects neuromuscular junction integrity and function. Biomaterials, 289, 121752.
23. Harrison, J. M., & Rafuse, V. F. (2020). Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A mice. Neurobiology of Disease, 145, 105052.
24. .Verma S., Khurana S., Vats A., Sahu B., Ganguly N.K., Chakraborti P., Gourie-Devi M., Taneja V. (2022) Neuromuscular Junction Dysfunction in Amyotrophic Lateral Sclerosis. Mol. Neurobiol., 59:1502–1527. Doi: 10.1007/s12035-021-02658-6.
25. Martin, S., Battistini, C., & Sun, J. (2022). A gut feeling in amyotrophic lateral sclerosis: microbiome of mice and men. Frontiers in cellular and infection microbiology, 12, 839526.
26. Fayemendy, P., Marin, B., Labrunie, A., Boirie, Y., Walrand, S., Achamrah, N., ... & Jésus, P. (2021). Hypermetabolism is a reality in amyotrophic lateral sclerosis compared to healthy subjects. Journal of the Neurological Sciences, 420, 117257.
27. Steyn, F. J., Ioannides, Z. A., Van Eijk, R. P., Heggie, S., Thorpe, K. A., Ceslis, A., ... & Ngo, S. T. (2018). Hypermetabolism in ALS is associated with greater functional decline and shorter survival. Journal of Neurology, Neurosurgery & Psychiatry, 89(10), 1016-1023.
28. Ferri, A., & Coccurello, R. (2017). What is “Hyper” in the ALS Hypermetabolism?. Mediators of inflammation, 2017(1), 7821672.
29. Harwood, C. A., Westgate, K., Gunstone, S., Brage, S., Wareham, N. J., McDermott, C. J., & Shaw, P. J. (2016). Long-term physical activity: an exogenous risk factor for sporadic amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17(5-6), 377-384.
30. Pupillo, E., Bianchi, E., Vanacore, N., Montalto, C., Ricca, G., Robustelli Della Cuna, F. S., ... & Beghi, E. (2020). Increased risk and early onset of ALS in professional players from Italian Soccer Teams. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21(5-6), 403-409.
31. Eisen, A., Kim, S., & Pant, B. (1992). Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron?. Muscle & nerve, 15(2), 219-224.
32. Zanette, G., Tamburin, S., Manganotti, P., Refatti, N., Forgione, A., & Rizzuto, N. (2002). Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clinical Neurophysiology, 113(11), 1688-1697.
33. Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000). El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders, 1(5), 293-299.
34. Appel, S. H., & Rowland, L. P. (2012). Amyotrophic lateral sclerosis, frontotemporal lobar dementia, and p62: a functional convergence?. Neurology, 79(15), 1526-1527.
35. Logroscino, G., Traynor, B. J., Hardiman, O., Couratier, P., Mitchell, J. D., Swingler, R. J., & Beghi, E. (2008). Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. Journal of Neurology, Neurosurgery & Psychiatry, 79(1), 6-11.
36. Murphy, N. A., Arthur, K. C., Tienari, P. J., Houlden, H., Chiò, A., & Traynor, B. J. (2017). Age-related penetrance of the C9orf72 repeat expansion. Scientific reports, 7(1), 2116.
37. Chiò, A., Moglia, C., Canosa, A., Manera, U., D'Ovidio, F., Vasta, R., ... & Calvo, A. (2020). ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology, 94(8), e802-e810.
38. https://www.nice.org.uk/guidance/ng42
39. https://www.cmaj.ca/content/cmaj/192/46/E1453.full.pdf.
40. Klavžar, P., Koritnik, B., Leonardis, L., Dolenc Grošelj, L., Kirbiš, M., Ristić Kovačič, S., ... & Zidar, J. (2020). Improvements in the multidisciplinary care are beneficial for survival in amyotrophic lateral sclerosis (ALS): experience from a tertiary ALS center. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21(3-4), 203-208.
41. Filippini, T., Fiore, M., Tesauro, M., Malagoli, C., Consonni, M., Violi, F., ... & Vinceti, M. (2020). Clinical and lifestyle factors and risk of amyotrophic lateral sclerosis: A population-based case-control study. International journal of environmental research and public health, 17(3), 857.
42. Oggiano, R., Pisano, A., Sabalic, A., Farace, C., Fenu, G., Lintas, S., ... & Madeddu, R. (2021). An overview on amyotrophic lateral sclerosis and cadmium. Neurological Sciences, 42, 531-537.
43. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., ... & Brown Jr, R. H. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362(6415), 59-62.
44. Renton, A. E., Chiò, A., & Traynor, B. J. (2014). State of play in amyotrophic lateral sclerosis genetics. Nature neuroscience, 17(1), 17-23.
45. Ito, D., Hatano, M., & Suzuki, N. (2017). RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration. Science Translational Medicine, 9(415), eaah5436.
46. Taylor, J. P., Brown Jr, R. H., & Cleveland, D. W. (2016). Decoding ALS: from genes to mechanism. Nature, 539(7628), 197-206.
47. Xue, Y. C., Ng, C. S., Xiang, P., Liu, H., Zhang, K., Mohamud, Y., & Luo, H. (2020). Dysregulation of RNA-binding proteins in amyotrophic lateral sclerosis. Frontiers in molecular neuroscience, 13, 78.
48. Dudman, J., & Qi, X. (2020). Stress granule dysregulation in amyotrophic lateral sclerosis. Frontiers in cellular neuroscience, 14, 598517.
49. Dervishi, I., Gozutok, O., Murnan, K., Gautam, M., Heller, D., Bigio, E., & Ozdinler, P. H. (2018). Protein-protein interactions reveal key canonical pathways, upstream regulators, interactome domains, and novel targets in ALS. Scientific reports, 8(1), 1-19.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 K. Sandhiya, Lavanya Babu, R. Swathi, S. Shakthi Sree, R. Srinivasan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
